a-randomized-controlled-trial-auricular-acupressure-combined-with

A Randomized Controlled Trial of Auricular Acupressure Combined with Sodium Hyaluronate for Abnormal Blink Reflex in Children

Abnormal blink reflex in children is a common ocular symptom with complex causes, including ocular surface diseases like dry eye and inflammation, as well ...

IL33/ST2 axis activates airway eosinophils that exacerbate airway inflammation. The data was obtained from PubMed, EMBASE, Clinical trial, Cochrane Library, Web of science, CNKI and Wanfang database with time restrictions of 1 Jan, 2000 to 15 Feb, 2016. The meta-analysis was performed using Review Manager 5.2 software. After searching, total 15 documents were included into this meta-analysis, involving in 633 asthma patients and 379 healthy people. The meta-analysis results revealed that the serum IL33 or ST2 level was higher in asthma patients compared to that in healthy people. (P=0.02, 95% CI (7.57, 72.74); P<0.0001, 95% CI (31.27, 91.32)). Compared to healthy people, severe, moderate or mild asthma patients had much higher serum IL33 level. (P<0.00001, 95% CI (87.86, 188.09); P<0.00001, 95% CI (31.93, 72.29); P<0.00001, 95% CI (100.51, 153.08), respectively). The serum ST2 level in different asthma progress included severe or moderate was higher, (P<0.00001, 95% CI (50.76, 76.93); P<0.00001, 95% CI (1.02, 1.79), respectively) but nor mild. (P=0.30, 95% CI (-22.37, 72.61)). The meta-analysis result shown the sputum IL33 was not higher in moderate asthma patients than that in healthy people. (P=0.20, 95% CI (-1.99, 9.52)) The meta-analysis results shown that there were significantly difference between and among two asthma progress, (P<0.00001, 95% CI (14.02, 19.09), severe vs moderate; P<0.00001, 95% CI (0.52, 1.24), moderate vs mild) However, there was no significant differences between severe group and mild group. (P=0.08, 95% CI (-20.95, 336.50)). Serum IL33 and ST2 level is relevant to asthma disease. With asthma disease progress, IL33 and ST2 are increased significantly.

Interleukin-33 and receptor ST2 as indicators in patients with asthma: a meta-analysis.

To investigate the association of osteopontin gene -443 C>T, -156 G>GG, and -1748 A>G polymorphisms with cancer risk. The Medline, PubMed, PUBMED, EMBASE and Web of Science databases were searched. Meta-analyses were conducted using RevMan 5.2 software. After searching and evaluating the included papers, total 10 documents involved in -443 C>T, 8 papers involved in four articles involved in -156 G>GG and -1748 A>G were included into this meta analysis. There were no significant differences in genotype osteopontin -443 C>T distribution between cancer cases and control (OR=0.98, 95% CI=0.68-1.40, P=0.90; OR=0.90, 95% CI=0.60-1.35, P=0.62; OR=0.98, 95% CI=0.59-1.64, P=0.94; OR=0.87, 95% CI=0.60-1.25, P=0.44, respectively). Meanwhile, no association between osteopontin -1748 A>G polymorphism and tumors under all genetic models. (OR=0.73, 95% CI=0.54-1.00, P=0.05; OR=0.95, 95% CI=0.82-1.10, P=0.48; OR=1.31, 95% CI=0.95-1.81, P=0.10; OR=0.90, 95% CI=0.77-1.06, P=0.20, respectively). However, osteopontin -156 G>GG polymorphism is only partly related to the tumor risk. (GGGG+GGG vs GG model, OR=1.21, 95% CI=1.01-1.46, P=0.04; GGG vs GG model: OR=1.19, 95% CI=1.05-1.35, P=0.008, respectively) osteopontin gene polymorphisms, -443 C>T and -1748 A>G was not associated with cancer risk, but partly associated to tumor risk for -156 G>GG gene polymorphism.

Association of osteopontin polymorphism with cancer risk: a meta-analysis.

We collected 96 patients who received dual immunotherapy between January 2019 and June 2024, in a 1:1:1 ratio based on PD-L1 expression levels of negative (<1%), medium (1% ≤ PD-L1 ≤ 49%), and high (PD-L1 ≥ 50%). This study evaluates the efficacy and safety of dual immunotherapy in patients with advanced NSCLC, stratified by PD-L1 expression levels. Among the 96 patients, the objective response rate (ORR) was 37.5%, disease control rate (DCR) was 67.8%. In the multivariate analysis of PFS, PD-L1 ≥ 50% (HR = 0.40, 95% CI: 0.22-0.74) was identified as a protective factor for PFS, while PS Score ≥ 2 (HR = 2.74, 95% CI: 1.11-6.77) and stage IV tumors (HR = 2.05, 95% CI: 1.02-4.12) were risk factors. In the multivariate analysis of OS, PD-L1 between 1% and 49% (HR = 0.51, 95% CI: 0.28-0.90) and PD-L1 ≥ 50% (HR = 0.31, 95% CI: 0.17-0.57) were protective factors, with no risk factors detected. The incidence of adverse events was 77.1%, with a 34.3% incidence of grade 3-4 immune-related adverse events. And PD-L1 ≥ 50% group adverse events incidence more common, with an overall incidence of 87.5% and a grade 3-4 incidence of 40.6%. Patients with high PD-L1 expression (≥50%) demonstrated improved progression-free survival (PFS, HR = 0.40) and overall survival (OS, HR = 0.31) but experienced a higher incidence of severe adverse events (40.6%).

Article	Year
Interleukin-33 and receptor ST2 as indicators in patients with asthma: a meta-analysis. International journal of clinical and experimental medicine\| PubMed ID: 26628975	2015
Association of osteopontin polymorphism with cancer risk: a meta-analysis. International journal of clinical and experimental medicine\| PubMed ID: 26885018	2015
Real-world single-center data analysis of dual immunotherapy in advanced NSCLC: Efficacy, survival, and adverse events. Human vaccines & immunotherapeutics\| PubMed ID: 40758627	2025

Gang Yang

Biography

JoVE Journal Publications

Other Publications